Success Metrics

Clinical Success Rate
81.5%

Based on 22 completed trials

Completion Rate
81%(22/27)
Active Trials
0(0%)
Results Posted
86%(19 trials)
Terminated
5(15%)

Phase Distribution

Ph phase_2
9
26%
Ph phase_1
1
3%
Ph phase_4
14
41%
Ph not_applicable
3
9%
Ph phase_3
7
21%

Phase Distribution

1

Early Stage

9

Mid Stage

21

Late Stage

Phase Distribution34 total trials
Phase 1Safety & dosage
1(2.9%)
Phase 2Efficacy & side effects
9(26.5%)
Phase 3Large-scale testing
7(20.6%)
Phase 4Post-market surveillance
14(41.2%)
N/ANon-phased studies
3(8.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

78.6%

22 of 28 finished

Non-Completion Rate

21.4%

6 ended early

Currently Active

0

trials recruiting

Total Trials

34

all time

Status Distribution
Completed(22)
Terminated(6)
Other(6)

Detailed Status

Completed22
unknown6
Terminated5
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
34
Active
0
Success Rate
81.5%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (2.9%)
Phase 29 (26.5%)
Phase 37 (20.6%)
Phase 414 (41.2%)
N/A3 (8.8%)

Trials by Status

unknown618%
completed2265%
terminated515%
withdrawn13%

Recent Activity

Clinical Trials (34)

Showing 20 of 34 trialsScroll for more
NCT02783430Phase 2

Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease

Completed
NCT01829243Phase 3

Milnacipran and Neurocognition, Pain and Fatigue in Fibromyalgia : A 13-week Randomized, Placebo Controlled Cross Over Trial

Completed
NCT01393522Not Applicable

Study Evaluated the Effectiveness of Milnacipran to Reduce Pain Levels in Individuals With Chronic Migraine

Completed
NCT05384210Not Applicable

Effect of Milnacipran / Gabapentin in Fibromyalgia

Unknown
NCT01288937Phase 3

A Placebo Controlled, Randomized, Double Blind Trial of Milnacipran for the Treatment of Idiopathic Neuropathy Pain

Terminated
NCT01337700Phase 4

Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism

Completed
NCT01125423Phase 4

Study of Fibromyalgia Treated With Milnacipran

Completed
NCT01234675Phase 4

The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia

Completed
NCT01328002Phase 2

Safety and Efficacy of Milnacipran in Pediatric Patients With Primary Fibromyalgia

Terminated
NCT01914042Phase 2

Prediction of Inter-individual Differences in the Response to Morphine Versus Milnacipran in Patients With Sciatica

Unknown
NCT01304589Phase 3

Savella in Treatment for Provoked Vestibulodynia

Completed
NCT01225991Phase 4

Milnacipran for Treatment of Pain in Older Adults With Rheumatoid Arthritis

Completed
NCT01173055Phase 4

A Study to Evaluate the Effects of Milnacipran on Pain Processing and Functional MRI in Patients With Fibromyalgia

Completed
NCT01471379Phase 2

Milnacipran (Savella) in Irritable Bowel Syndrome (IBS)

Terminated
NCT01108731Phase 2

The Effect of Milnacipran in Patients With Fibromyalgia

Completed
NCT01359826Phase 4

The Effect of Milnacipran on Fatigue and Quality of Life in Lupus Patients

Withdrawn
NCT01510457Phase 4

Milnacipran for Chronic Pain in Knee Osteoarthritis

Completed
NCT01207453Phase 4

Milnacipran in the Treatment of Widespread, Non-Joint Pain in Rheumatoid Arthritis

Completed
NCT01294059Phase 1

Effects of Milnacipran on Widespread Mechanical and Thermal Hyperalgesia of Fibromyalgia Patients

Completed
NCT01777581Phase 4

Milnacipran for Lumbosacral Radicular Pain

Completed

Drug Details

Intervention Type
DRUG
Total Trials
34